Eli Lilly, post approval from the Drug Controller General of India (DCGI), has launched of Copellor (Ixekizumab) in India. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as treatment of adult patients with active psoriatic arthritis.
A humanised IgG4 monoclonal antibody, Copellor (Ixekizumab) is designed to specifically target IL-17A, a protein that plays a role in triggering and maintaining inflammation in psoriasis.
Vineet Gupta, MD, Eli Lilly and Company – India & India Subcontinent said, “Our foray into the dermatology segment strengthens Lilly’s promise of bringing innovative medicines to India. Global studies show that the impact psoriasis has on a patient’s quality of life is comparable to that of ‘serious’ diseases such as cancer and heart failure. The availability of a new treatment like Copellor (Ixekizumab) will now empower healthcare providers with another option for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as treatment of adult patients with active psoriatic arthritis, a huge unmet need in the country.”
Copellor (Ixekizumab) is available as an 80 mg/ml single dose prefilled autoinjector.